top stories

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

Yesterday
Deals

Covid-19 roundup: Eu­rope pur­chas­es 80M dos­es of Mod­er­na's vac­cine; CO­V­AXX se­cures $2.8B in emerg­ing mar­ket pre-or­ders

3 days ago
Coronavirus

Chi­na opens the door for biotech in­vestors in Hong Kong to buy Shang­hai stocks, and vice ver­sa

3 days ago
IPOs
China

Latest

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

3 days ago
Coronavirus
Manufacturing

FDA hands Liq­uidia and Re­vance a CRL and de­fer­ral, re­spec­tive­ly, as Covid-19 cre­ates in­spec­tion chal­lenge

3 days ago
Regulatory
Coronavirus

News brief­ing: FDA re­quests new tri­al for Reata's Friedre­ich's atax­ia pro­gram; J&J's Trem­fya picks up ex­pand­ed la­bel ...

3 days ago
News Briefing

Jef­frey Hat­field takes over from Diego Mi­ralles as CEO of Vi­vid­ion; Drag­on­fly scores a new ex­ec with COO Alex ...

3 days ago
Peer Review
see latest stream
People

Plot thick­ens around Leg­end Biotech, Gen­Script with founder Frank Zhang's ar­rest

5 days ago

Vivek Ra­maswamy’s Meta­vant hits a brick wall, aban­don­ing a lead pro­gram for di­a­betes. And there’s noth­ing vis­i­ble ...

Last week

For­mer MiMedx CEO and COO are con­vict­ed on fraud, con­spir­a­cy charges

Last week
Startups

Af­ter 5 qui­et years, a for­mer Scripps spin­out rais­es $200M and an­nounces plans to try again at an IPO

4 days ago

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

5 days ago

George Church backs a start­up so­lu­tion to the mas­sive gene ther­a­py man­u­fac­tur­ing bot­tle­neck

Last week
Deals

Bris­tol My­ers fronts new Schrödinger al­liance with $55M up­front, ex­pand­ing pre­ci­sion on­col­o­gy pro­file

5 days ago

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

5 days ago

In an ap­par­ent R&D about-face, Eli Lil­ly part­ners with Pre­ci­sion Bio­Sciences on genome edit­ing in a deal worth up to ...

Last week
IPOs

Overnight for­tunes are be­ing made in biotech these days — and it's both en­cour­ag­ing and more than a lit­tle bit ...

4 days ago

From a pair of Air Jor­dans to a $200M-plus IPO, Carl Hansen is craft­ing an overnight R&D for­tune fu­eled by Covid-19

5 days ago

Sean Bo­hen hauls in a mul­ti­mil­lion-dol­lar wind­fall as his new­ly adopt­ed biotech bags a $209M-plus IPO

Last week

Premium storiesSee all

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more ...

4 days ago
Bioregnum
Regulatory

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

5 days ago
R&D

Scoop: SR One crew com­pletes a com­pli­cat­ed spin­out from Glax­o­SmithK­line. And now they have a $500M fund to in­vest on ...

Last week
Venture

Rene­go­ti­ate the $6B CVR deal Bris­tol My­ers made for the Cel­gene buy­out? Caforio says that’s not hap­pen­ing

Last week
Deals

Don't missSee all

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D ...

4 days ago
R&D

Covid-19 roundup: Rus­sia prices vac­cine 't­wo or more times cheap­er' than mR­NA shots; Sino­vac PhI­II da­ta ex­pect­ed in ...

4 days ago
Coronavirus

Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

4 days ago
Pharma
Regulatory

Tech bil­lion­aire Pe­ter Thiel backs a lead­ing psy­che­del­ic drug de­vel­op­er

5 days ago
Venture

Endpoints Standouts

The End­points 11: Here are some of the most promis­ing star­tups in biotech. And Covid-19 is­n't go­ing to stop them

Last month
Startups
In Focus

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

7 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

11 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

Last year
People
R&D

Peer review See all

Nov
20

Jen­nifer Zi­olkows­ki re­signs from CFO post at Sol­id Bio­sciences; Sean Bo­hen's Ole­ma On­col­o­gy adds San­dra Horn­ing to ...

Nov
13

Af­ter No­vo Nordisk's ac­qui­si­tion of Cor­vidia, Ram Ai­yar takes the helm at Ko­r­ro Bio; Sil­ver­back gets a new CFO to go ...

Nov
6

Karin Rosén moves on from GSK, now play­ing dual roles at Hori­zon; Gilead looks to Jared Baeten to take com­mand of ...

Oct
30

Trou­bled Unum re­brands as Co­gent Bio­sciences, re­places CEO Chuck Wil­son with An­drew Rob­bins; Jen­nifer Fox ap­point­ed ...

Oct
23

Arndt Rolfs steps aside as Cen­to­gene CEO, with An­drin Os­wald named as his suc­ces­sor; João Sif­fert lands an­oth­er CEO ...

R&D channel feed

3 days ago

Urovan­t's lead drug dis­ap­points in mid-stage study as first big FDA de­ci­sion looms

Just as Urovant gets ready for its first big FDA de­ci­sion on vibegron, the drug has flopped in what would’ve been a fol­low-on in­di­ca­tion.

READ MORE

Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

4 days ago

Am­gen sev­ers 14-year Cy­to­ki­net­ics part­ner­ship, bail­ing on ome­cam­tiv af­ter mixed PhI­II re­sults

5 days ago
latest in R&D

Look­ing for leg up in he­mo­phil­ia B gene ther­a­py race, uniQure flash­es da­ta that helped lead to $2B CSL deal

Last week
Cell/Gene Tx

Gilead touts piv­otal da­ta for new kind of HIV ther­a­py, open­ing to­wards large po­ten­tial mar­ket

Last week

Bris­tol My­ers Squibb Foun­da­tion launch­es pro­gram to tack­le di­ver­si­ty prob­lem in clin­i­cal tri­als

Last week
Pharma

GSK and Vi­iV score break­through ther­a­py des­ig­na­tion in HIV pre­ven­tion, as Tru­va­da show­down draws near­er

Last week
Regulatory

BeiGene beefs up PD-1 da­ta with pos­i­tive PhI­II re­sults for tislelizum­ab, this time in metasta­t­ic NSCLC

Last week
see latest stories

Pharma channel feed

3 days ago

Bax­ter con­tin­ues on-shoring push with $50M In­di­ana ex­pan­sion

It's been a ban­ner year for the once hum­drum busi­ness of man­u­fac­tur­ing drugs, par­tic­u­lar­ly vac­cines. Bil­lions have been spent ramp­ing up fa­cil­i­ties for Covid-19 jabs, while in­di­vid­ual ...

READ MORE

Eu­ro­pean Union aims to es­tab­lish patent workaround in case of emer­gen­cies while try­ing to strength­en its own IP

3 days ago

Pur­due Phar­ma pleads guilty in fed­er­al Oxy­Con­tin probe, for­mal­ly rec­og­niz­ing it played a part in the opi­oid cri­sis

4 days ago
latest in Pharma

PhRMA sues Trump gov­ern­ment over drug im­por­ta­tion rule — days be­fore it's set to be ef­fec­tive

4 days ago

Roche tacks on an­oth­er Xofluza in­di­ca­tion as flu sea­son meets pan­dem­ic

4 days ago
Regulatory

A poll sug­gests vac­cine da­ta boost­ed Pfiz­er's pub­lic im­age, but oth­er da­ta point to long road ahead

4 days ago
Coronavirus

With on­ly weeks left in his pres­i­den­cy, Trump makes a fi­nal, long-shot bid to re­make US drug pric­ing

Last week

J&J joins Bris­tol My­ers Squibb with $100M com­mit­ment to di­ver­si­ty ef­forts

Last week
see latest stories

Coronavirus channel feed

5 days ago

Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half af­ter be­com­ing the ex­per­i­men­tal treat­ment of choice for a new­ly di­ag­nosed pres­i­dent, Re­gen­eron's an­ti­body cock­tail has re­ceived emer­gency use au­tho­riza­tion from ...

READ MORE

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

5 days ago

It's of­fi­cial: Pfiz­er and BioN­Tech have sub­mit­ted their Covid-19 vac­cine to the FDA — and the agency cir­cled a date ...

Last week
latest in Coronavirus

Pfiz­er and BioN­Tech are send­ing the first Covid-19 vac­cine to the FDA to­day

Last week

Covid-19 roundup: WHO rec­om­mends against 'high cost' remde­sivir, dis­ap­point­ing Gilead; EU deals with Pfiz­er/BioN­Tech, Cure­Vac top $10B — re­port

Last week

Eli Lil­ly picks up an­oth­er Covid-19 EUA as reg­u­la­tors wave through its Olu­mi­ant plus remde­sivir com­bo

Last week

CEO Ugur Sahin: BioN­Tech and Pfiz­er will file for a Covid-19 vac­cine EUA on Fri­day

Last week
Regulatory

A new study breathes life in­to an all-but-dead ap­proach to treat­ing se­vere Covid-19

Last week
see latest stories